GlassScriptPhysician profile
Matthew J Jones
NPI 1437887361
$5,683.75
in general payments reported to CMS, 2019-2025
48 companies · $521 in 2025
The $521 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $266 · 2023: $2,634 · 2024: $2,262 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,884 · Education: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,884.33 |
| Education | $532.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $830.92 | 2022-2024 | Myrbetriq, Xtandi |
| Axonics, INC. | $687.27 | 2023-2024 | Bulkamid, Axonics |
| Dendreon Pharmaceuticals LLC | $542.28 | 2023-2024 | Provenge |
| Coloplast Corp | $420.70 | 2023-2024 | Speedicath |
| Merck Sharp & Dohme LLC | $339.04 | 2023-2024 | Keytruda, Lynparza |
| Medtronic, INC. | $316.34 | 2023-2024 | Interstim, Minimed 780g, Nuro |
| Ferring Pharmaceuticals INC. | $181.06 | 2023-2024 | Adstiladrin |
| 180 Medical, INC. | $151.91 | 2022-2024 | Gentlecath Glide |
| Teleflex LLC | $142.51 | 2023 | Urolift |
| Sumitomo Pharma America, INC. | $140.39 | 2023-2024 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $133.86 | 2023-2024 | Prolaris |
| Antares Pharma, INC. | $127.03 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $125.04 | 2023 | Lynparza |
| Hologic Sales and Service, LLC | $124.99 | 2025 | Aptima |
| Urogen Pharma, INC. | $123.49 | 2022-2024 | Jelmyto |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $104.00 | 2023-2025 | Jatenzo |
| Lilly USA, LLC | $101.35 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Urovant Sciences INC | $100.95 | 2022 | |
| Olympus America INC. | $72.23 | 2023-2024 | Itind System |
| Insulet Corporation | $67.78 | 2025 | Omnipod |
| Endo Pharmaceuticals INC. | $61.88 | 2023-2024 | Aveed, Xiaflex, Edex |
| Novo Nordisk INC | $61.80 | 2024-2025 | Rybelsus, Wegovy, Ozempic |
| Halozyme INC | $61.59 | 2023 | |
| Janssen Scientific Affairs, LLC | $55.31 | 2024 | Erleada, Akeega |
| Shield Therapeutics INC | $50.62 | 2025 | |
| Janssen Biotech, INC. | $41.21 | 2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $39.84 | 2023 | |
| Glaxosmithkline, LLC. | $35.79 | 2024-2025 | Shingrix |
| Telix Pharmaceuticals | $32.92 | 2022-2023 | Illuccix |
| Myovant Sciences INC. | $32.40 | 2022 | |
| Amgen INC. | $32.35 | 2023-2024 | Xgeva, Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $31.97 | 2022-2023 | Jynarque |
| Ascendis Pharma Endocrinology INC | $28.20 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $27.59 | 2025 | Unithroid |
| Almatica Pharma LLC | $25.32 | 2025 | Teriparatide |
| Foundation Medicine, INC. | $22.15 | 2023 | |
| Inspire Medical Systems, INC. | $20.73 | 2024 | Inspire |
| Dexcom, INC. | $20.00 | 2024 | Dexcom G6 Transmitter |
| Immunitybio, INC. | $18.97 | 2024 | |
| Gilead Sciences, INC. | $18.82 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $17.91 | 2022 | |
| Verity Pharmaceuticals INC. | $17.62 | 2023 | Trelstar |
| Mannkind Corporation | $17.55 | 2025 | |
| Astellas Pharma Global Development | $16.66 | 2024 | Xtandi |
| Exact Sciences Corporation | $16.36 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $16.21 | 2023 | |
| Ani Pharmaceuticals, INC. | $14.53 | 2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $14.31 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.